** Shares of Israel-based medical device maker IceCure Medical ICCM.O fall 17% to $1.22 in afternoon trading, their biggest one-day percentage fall in more than a year
** ICCM says it expects the FDA to make a decision on its ProSense system, used for the treatment of a type of breast cancer, after Q1 2025
** Co previously expected FDA's decision by Q1 2025
** Co's ProSense provides a minimally invasive treatment option to destroy tumors by freezing them
** ICCM has risen 19.4% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。